Bristol Myers (BMY) RayzeBio president gains stock as RSUs vest

Rhea-AI Filing Summary

Bristol Myers Squibb executive Benjamin Hickey, President of the RayzeBio organization, reported equity compensation activity involving restricted stock units and common stock. On February 27, 2026, 3,286 restricted stock units were exercised or converted into 3,286 shares of common stock at $0.00 per share as they vested. In connection with this vesting, 1,672 common shares were withheld at $62.37 per share to cover tax obligations, a non‑open‑market disposition. After these transactions, Hickey directly held 16,672 shares of Bristol Myers Squibb common stock.

Insider Trade Summary

3,286 shares exercised/converted

Mixed 3 txns

Insider Hickey Benjamin

Role President, RayzeBio Org.

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	3,286	$0.00	--
Exercise	Common Stock, $0.10 par value	3,286	$0.00	--
Tax Withholding	Common Stock, $0.10 par value	1,672	$62.37	$104K

Holdings After Transaction: Restricted Stock Units — 3,286 shares (Direct); Common Stock, $0.10 par value — 18,344 shares (Direct)

Footnotes (1)

1. The restricted stock units vest in three equal installments beginning on March 1, 2025. Shares withheld for payment of taxes upon vesting of award. Each restricted stock unit converts into one share of common stock upon vesting.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hickey Benjamin

(Last) (First) (Middle)

BRISTOL-MYERS SQUIBB COMPANY

ROUTE 206 AND PROVINCE LINE ROAD

(Street)

PRINCETON NJ 08543

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BRISTOL MYERS SQUIBB CO [ BMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, RayzeBio Org.

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.10 par value	02/27/2026		M		3,286(1)	A	$0	18,344	D
Common Stock, $0.10 par value	02/27/2026		F		1,672(2)	D	$62.37	16,672	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(3)	02/27/2026		M			3,286	(1)	03/01/2027	Common Stock, $0.10 par value	3,286	$0	3,286	D

Explanation of Responses:

1. The restricted stock units vest in three equal installments beginning on March 1, 2025.

2. Shares withheld for payment of taxes upon vesting of award.

3. Each restricted stock unit converts into one share of common stock upon vesting.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Amy Fallone, attorney-in-fact for Benjamin Hickey	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BMY executive Benjamin Hickey report in this Form 4 filing?

Benjamin Hickey reported routine equity compensation activity. 3,286 restricted stock units vested and converted into the same number of Bristol Myers Squibb common shares, and 1,672 of those shares were withheld to satisfy tax obligations related to the vesting event, leaving him with 16,672 shares.

How many Bristol Myers Squibb (BMY) shares did Hickey acquire from RSU vesting?

He acquired 3,286 Bristol Myers Squibb common shares through the exercise or conversion of 3,286 restricted stock units. Each restricted stock unit converted into one share of common stock upon vesting, consistent with the award’s stated terms, at a price of $0.00 per share.

Why were some BMY shares disposed of in Benjamin Hickey’s Form 4?

The 1,672 common shares were withheld to pay taxes owed at vesting. This tax-withholding disposition, priced at $62.37 per share, is a standard administrative mechanism and does not represent an open-market sale initiated for investment or trading purposes by the executive.

What is Benjamin Hickey’s Bristol Myers Squibb (BMY) share ownership after these transactions?

After the reported vesting and related tax withholding, Benjamin Hickey directly owns 16,672 shares of Bristol Myers Squibb common stock. This figure reflects the net position following the 3,286-share RSU conversion and the 1,672-share tax-withholding disposition on February 27, 2026.

How do Hickey’s restricted stock units in BMY vest according to the filing footnotes?

The restricted stock units vest in three equal installments beginning on March 1, 2025. Upon each vesting event, every restricted stock unit converts into one share of Bristol Myers Squibb common stock, with shares potentially withheld to cover applicable tax liabilities at that time.